Keywords: Amarin, Ethyl Eicosapent, EMEA, MA withdrawal, Huntington's disease

Amarin Neuroscience withdraws MA application for Ethyl Eicosapent Soft Capsules

Article | 9 December 2009

The European Medicines Agency (EMEA) says it has been formally notified by Ireland-based Amarin Neuroscience of its decision to withdraw its application for a centralized marketing authorization for Ethyl Eicosapent (ethyl eicosapent), 500mg soft gelatine capsules.

E Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.

FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!

Sign up in less than 60 seconds...no payment needed

Want to read the full article?
Take a 30 day FREE Trial worth £60

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in